Mereo BioPharma (MREO) Debt Ratio (2017 - 2024)

Mereo BioPharma's (MREO) quarterly Debt Ratio came in at 0.07 in Q4 2024, up 15.84% quarter-over-quarter from 0.06 in Q3 2024.

Analysis

Mereo BioPharma (MREO) Debt Ratio (2017 - 2024) Analysis & Trends

Mereo BioPharma (MREO) has reported Debt Ratio for 5 consecutive years, with 0.07 the latest figure, recorded in Q4 2024.

On a quarterly basis, Debt Ratio changed N/A year-over-year to 0.07 in Q4 2024; TTM through Dec 2024 was 0.07, a N/A change from a year earlier, with the FY2024 full-year figure at 0.07, changed N/A from the prior year.
Debt Ratio was 0.07 for Q4 2024 at Mereo BioPharma, up from 0.06 in the prior quarter.
Over five years, Debt Ratio peaked at 0.37 in Q2 2020 and troughed at 0.05 in Q2 2024.

Peer Set

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Debt Ratio (Qtr)
1	Amgen	206.44 Bn	192.45 Bn	7.24 Bn	0.66
2	Gilead Sciences	179.97 Bn	176.79 Bn	6.22 Bn	0.58
3	Vertex Pharmaceuticals	130.57 Bn	122.72 Bn	2.84 Bn	-
4	Regeneron Pharmaceuticals	81.63 Bn	73.63 Bn	3.93 Bn	0.05
5	Argenx Se	60.34 Bn	55.16 Bn	1.37 Bn	-
6	Moderna	54.37 Bn	49.23 Bn	52.00 Mn	0.05
7	Alnylam Pharmaceuticals	33.07 Bn	29.76 Bn	992.69 Mn	-
8	Biogen	31.84 Bn	30.55 Bn	1.96 Bn	0.25
9	Roivant Sciences	29.49 Bn	29.49 Bn	1.16 Mn	-
10	Mereo BioPharma	38.92 Mn	38.92 Mn	-	-

Historic Data

Download Data